Implant date - estimated.There was no reported device malfunction and the product was not returned as the scaffold remains in the anatomy.A review of the lot history record and complaint history could not be conducted because the lot number was not provided.The reported patient effects of thrombosis and myocardial infarction, as listed in the absorb gt1 instructions for use (ifu), are known patient effects that may be associated with the use of a coronary scaffold in native coronary arteries.Based on the case information, a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined.The reported treatment appears to be related to the circumstances of the procedure.There is no indication of a product quality issue with respect to design, manufacture or labeling of the device.
|
It was reported that the an absorb bioresorbable vascular scaffold (bvs) was implanted sometime in (b)(6) 2014 to treat an anterior myocardial infarct in the ramus interventricularis anterior (riva).Seven years later, on (b)(6) 2021, the patient was hospitalized with a myocardial infarct due to an angiographically proven very late thrombosis of the bvs.Of note, the bvs was fully absorbed and the area endothelialized, with only signs of the markers visible.The vessel was dilated with an unspecified 2.5 x 15 mm balloon and a non-abbott 3.5 x 23 mm stent was implanted.Patient did very well and has been discharged from the hospital.No additional information was provided.
|